Whither pathogenetic treatments for diabetic polyneuropathy?

Summary Diabetic distal symmetric polyneuropathy (DSPN) occurs in around one‐third of patients with diabetes and is associated with significant morbidity and increased mortality. Diagnosis and clinical assessment of DSPN remain a challenge, not only for the physician in clinical practice but also fo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes/metabolism research and reviews 2013-07, Vol.29 (5), p.327-333
Hauptverfasser:	Boulton, Andrew J. M., Kempler, Peter, Ametov, Alexander, Ziegler, Dan
Format:	Artikel
Sprache:	eng
Schlagworte:	Aldehyde Reductase - antagonists & inhibitors Animals Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - therapy Diabetic Neuropathies - diagnosis Diabetic Neuropathies - drug therapy Diabetic Neuropathies - physiopathology Diabetic Neuropathies - prevention & control diabetic peripheral neuropathy Disease Progression Enzyme Inhibitors - therapeutic use glycaemic control Humans Hyperglycemia - prevention & control neuropathy diagnosis pain management Pain Management - trends pathogenetic treatment Polyneuropathies - diagnosis Polyneuropathies - drug therapy Polyneuropathies - physiopathology Polyneuropathies - prevention & control Vasodilator Agents - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!